Healthcare cybersecurity · Connected asset / IoMT risk
Ordr
Ordr provides connected-asset and IoMT risk management for healthcare and other industries that run large fleets of medical and IoT devices. It is not a clinical identity product.
Strong fit
- Health systems that need visibility and risk controls across medical, IoT, and OT assets
- Security teams measuring unknown-device coverage, vulnerability exposure, and segmentation readiness
- Buyers comparing purpose-built connected-device platforms rather than generic IT discovery alone
Weak fit
- Organizations that only need a HIPAA policy binder without device inventory work
- Buyers shopping a clinical identity or SSO product
- Teams that will not act on device risk findings after the dashboard lights up
Bottom line
Ordr earns a Recommend for health-system security teams that need connected-device and IoMT asset risk management beyond a spreadsheet inventory. Outcomes show up when unknown devices become classified, risk-ranked, and ready for segmentation or patch workflows. Product strength is AI-oriented asset risk across medical and enterprise connected devices; co-founder Pandian Gnanaprakasam returned as CEO in 2025. Implementation needs network access and security ownership. Pricing is quote-based. Third-party revenue estimates commonly sit near $25M to $35M with funding above $90M, under the hard cap and inside a realistic mid-market band. Score sits with Claroty on overall for a connected-asset lane, above Cylera, Cynerio, and Asimily on this IoMT-oriented board.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Ordr (ordr.net) provides an AI-powered platform for discovering, classifying, and managing risk on connected medical, IoT, and OT assets. Co-founder Pandian Gnanaprakasam serves as CEO after returning to the role in 2025.
It is device and asset risk infrastructure, not a compliance binder service. Compare Cylera, Asimily, and Cynerio on IoMT-focused shortlists, Claroty when broader CPS security is in scope, and Clearwater when the buy is healthcare risk and compliance advisory plus software.
Score reflects strong visibility and risk outcomes in the IoMT peer set with typical enterprise quote opacity.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Ordr | 7.5 | 7.2 |
| Cylera | 7.4 | 7.0 |
| Claroty | 7.5 | 7.1 |
| Cynerio | 7.3 | 7.0 |
| Asimily | 7.2 | 6.8 |
| MedCrypt | 7.1 | 6.9 |
Pricing
| Item | Detail |
|---|---|
| Model | Connected-asset risk platform packaging; quote-based. |
| What usually drives cost | Device count, sites, modules (visibility, risk, enforcement), and support. |
| What to ask in diligence | Annual platform cost at your connected-device count, with healthcare workflow and integration scope defined. |
| Published pricing | Public list price: not published. Expect device-volume platform pricing. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Ordr to function | |
| Named security or clinical-engineering owner | Dashboards without owners become wallpaper. |
| Baseline unknown-device count and critical vulnerability exposure captured | You cannot prove value without a before number. |
| Network tap or sensor placement plan agreed with networking | Blind spots recreate false confidence. |
| Response owners for device risk findings after go-live | Unworked findings are not risk reduction. |
| Change-control path for segmentation or patching defined | Findings without action waste the license. |
| What will maximize your value | |
| Track unknown-to-known device coverage weekly for 90 days | Alert volume is not outcomes. |
| Start with one clinical network segment first | Narrow wins beat empty enterprise banners. |
| Close or accept top critical device risks in a standing huddle | Silent aging hides failure. |
| Retire duplicate spreadsheet inventories after parallel month | Dual inventories double work. |
| Publish a monthly device-risk digest to CIO and clinical engineering | Hidden exposure surprises leadership. |
| Deal-breakers | |
| Nobody will own device-risk findings. | |
| Networking will not allow the visibility path the product needs. | |
| You expect a policy binder alone to replace device inventory. | |
| Leadership will not fund remediation after findings. | |
| Biomed will not partner on clinical device changes. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Scope & baseline | 2-4 weeks - Segments, sensors, baseline inventory. |
| 2 | Deploy | 4-10 weeks - Sensors/integrations; classify assets. |
| 3 | Pilot | 4-8 weeks - One site; risk workflow live. |
| 4 | Scale | 2-6 months - Add sites; enforce segmentation where approved. |
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category actually buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.